行情

IMMP

IMMP

Immutep
NASDAQ

实时行情|Nasdaq Last Sale

1.050
0.000
0.00%
休市 16:00 07/02 EDT
开盘
1.060
昨收
1.050
最高
1.080
最低
1.030
成交量
8.30万
成交额
--
52周最高
3.100
52周最低
0.5300
市值
4,082.37万
市盈率(TTM)
-0.3370
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测IMMP价格均价为3.530,最高价位5.04,最低价为2.017。

EPS

IMMP 新闻

更多
Immutep Completes Recruitment for Part A of Phase II TACTI-002 Study
Completes recruitment of patients with first line Non-Small Cell Lung Cancer (NSCLC)81 patients out of up to 109 now participating across the trial, with recruitment continuing.
GlobeNewswire · 6天前
Immutep receives A$1,437,826 R&D Tax Incentive
GlobeNewswire · 06/22 13:00
MFGP, AAXN among premarket gainers
Seeking Alpha - Article · 06/01 13:18
Immutep Surges In Pre-Market On Positive Efti Cancer Data
SmarterAnalyst · 06/01 12:40
26 Stocks Moving in Monday's Pre-Market Session
Gainers Digital Ally, Inc. (NASDAQ: DGLY) rose 185.7% to $3.20 in pre-market trading after surging over 33% on Friday.
Benzinga · 06/01 11:02
Immutep reports encouraging preliminary data on lead drug eftilagimod alpha
Seeking Alpha - Article · 06/01 10:36
Immutep Reports First Results from INSIGHT-004 Study at ASCO; Says Encouraging Early Activity Signals in a Variety of Cancer Indications
Immutep Limited (NASDAQ: IMMP) is pleased to report first interim data from its ongoing INSIGHT-004 Phase I clinical trial.
Benzinga · 06/01 10:17
Immutep Reports First Results from INSIGHT-004 Study; Says Encouraging Early Activity Signals in a Variety of Cancer Indications
Immutep Limited (NASDAQ: IMMP) is pleased to report first interim data from its ongoing INSIGHT-004 Phase I clinical trial.
Benzinga · 06/01 10:15

所属板块

生物技术和医学研究
+0.67%
制药与医学研究
+0.61%

热门股票

代码
价格
涨跌幅

IMMP 简况

Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.
展开

微牛提供Immutep Ltd(NASDAQ-IMMP)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的IMMP股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易IMMP股票基本功能。